Is massive scale proteomics causing a paradigm shift in biomarker discovery?
ABSTRACT
In this 45-minute talk, Dr. Stefánsson will discuss the largest population proteomics study ever performed to help provide more insight on disease and health outcomes. This collaborative research assembled expertise from deCODE Genetics and SomaLogic to combine the study of genetic and protein diversity to characterize disease biomarkers in the human population. The data from this type of proteomic study will inform drug discovery and development as well as improvements in health management. You will learn about:
- The high-throughput technologies that made this study possible
- The application of population proteomics in diagnosis and management of common and rare diseases
Dr. Kári Stefánsson
CEO, deCode Genetics
Kári Stefánsson is an Icelandic neurologist and founder and CEO of Reykjavik-based biopharmaceutical company deCODE genetics. In Iceland he has pioneered the use of population-scale genetics to understand variation in the sequence of the human genome.
More webinars
WebinarFinding the signal: Identifying reproducible biomarkers in high-plex proteomics
In biomarker discovery, the challenge is rarely a lack of data. Rather, it is knowing how to separate meaningful biological signal from technical distraction. This webinar focuses on how to use univariate analysis as a practical and powerful entry point for biomarker discovery in high-plex proteomics studies.
WebinarMore than the sum of its parts: How harmonized proteomic data reveals meaning across disparate clinical cohorts
Proteomics data generated across sites, time points, and workflows can be difficult to compare using standard normalization alone. This webinar shows how harmonization aligns datasets into a shared biological framework and reveals signals across studies and cohorts, highlighted through the GNPC’s analysis of 40,000 patient samples.
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.